details

Peer companies

;

Share Market News

The sales figure stood at Rs. 617.99 millions for the December 2019 quarter. The mentioned figure indicates a growth of about 28.37% as compared to Rs. 481.43 millions during the year-ago period.The Net Profit of the company reported a remarkable increase of 237.07% to Rs. 29.19  millions  from Rs. 8.66 millions in previous same quarter.The company reported a good operating profit of 80.78 millions compared to 44.82 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201912 201812 % Var 201912 201812 % Var 201903 201803 % Var Sales 617.99 481.43 28.37 1653.94 1106.69 49.45 1676.77 1072.36 56.36 Other Income 21.14 30.21 -30.02 113.43 119.46 -5.05 135.25 242.69 -44.27 PBIDT 80.78 44.82 80.23 232.19 125.51 85.00 166.87 58.83 183.65 Interest 11.95 13.19 -9.40 38.06 13.94 173.03 32.20 3.92 721.43 PBDT 68.83 31.63 117.61 194.13 111.57 74.00 134.67 43.30 211.02 Depreciation 21.90 22.97 -4.66 66.55 49.59 34.20 72.64 36.67 98.09 PBT 46.93 8.66 441.92 127.58 61.98 105.84 62.03 6.63 835.60 TAX 17.74 0.00 0.00 -17.68 0.00 0.00 -13.83 28.67 -148.24 Deferred Tax 10.11 -1.93 -623.83 -27.26 -7.73 252.65 0.00 0.00 0.00 PAT 29.19 8.66 237.07 145.26 61.98 134.37 75.86 -22.04 -444.19 Equity 496.74 487.47 1.90 496.74 487.47 1.90 487.47 487.47 0.00 PBIDTM(%) 13.07 9.31 40.40 14.04 11.34 23.79 9.95 5.49 81.41

Sequent Scientific is currently trading at Rs. 71.15, up by 1.50 points or 2.15% from its previous closing of Rs. 69.65 on the BSE.The scrip opened at Rs. 70.00 and has touched a high and low of Rs. 72.15 and Rs. 69.05 respectively. So far 33055 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 89.00 on 22-Jan-2019 and a 52 week low of Rs. 42.45 on 11-Oct-2018.Last one week high and low of the scrip stood at Rs. 72.15 and Rs. 67.50 respectively. The current market cap of the company is Rs. 1755.25 crore.The promoters holding in the company stood at 56.50%, while Institutions and Non-Institutions held 12.32% and 31.18% respectively.Sequent Scientific’s wholly owned subsidiary -- Sequent Research (SRL) has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its GLP compliant, Analytical services laboratory at Bengaluru.Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world`s largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.

The topline advanced to Rs. 520.75 millions, up 98.12% for the June 2019 quarter as against Rs. 262.85 millions during the year-ago period.Profit after Tax for the quarter ended June 2019 saw a decline of -45.67% from Rs. 26.19 millions to Rs. 14.23  millions.OP of the company witnessed a marginal growth to 50.80 millions from 35.09 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201906 201806 % Var 201906 201806 % Var 201903 201803 % Var Sales 520.75 262.85 98.12 520.75 262.85 98.12 1676.77 1072.36 56.36 Other Income 20.31 43.56 -53.37 20.31 43.56 -53.37 135.25 242.69 -44.27 PBIDT 50.80 35.09 44.77 50.80 35.09 44.77 166.87 58.83 183.65 Interest 14.20 0.13 10823.08 14.20 0.13 10823.08 32.20 3.92 721.43 PBDT 36.60 34.96 4.69 36.60 34.96 4.69 134.67 43.30 211.02 Depreciation 22.37 8.77 155.07 22.37 8.77 155.07 72.64 36.67 98.09 PBT 14.23 26.19 -45.67 14.23 26.19 -45.67 62.03 6.63 835.60 TAX 0.00 0.00 0.00 0.00 0.00 0.00 -13.83 28.67 -148.24 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 14.23 26.19 -45.67 14.23 26.19 -45.67 75.86 -22.04 -444.19 Equity 487.47 487.47 0.00 487.47 487.47 0.00 487.47 487.47 0.00 PBIDTM(%) 9.76 13.35 -26.93 9.76 13.35 -26.93 9.95 5.49 81.41

The Total revenue for the quarter ended March 2019 of  Rs. 570.08 millions grew by 112.76% from Rs. 267.95 millions.The Total Profit for the quarter ended March 2019 of Rs. 13.88 millions grew from Rs.-40.49 millionsOP of the company witnessed a marginal growth to 41.36 millions from 6.82 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201903 201803 % Var 201903 201803 % Var 201903 201803 % Var Sales 570.08 267.95 112.76 1676.77 1072.36 56.36 1676.77 1072.36 56.36 Other Income 15.79 50.94 -69.00 135.25 242.69 -44.27 135.25 242.69 -44.27 PBIDT 41.36 6.82 506.45 166.87 58.83 183.65 166.87 58.83 183.65 Interest 18.26 0.81 2154.32 32.20 3.92 721.43 32.20 3.92 721.43 PBDT 23.10 -5.60 -512.50 134.67 43.30 211.02 134.67 43.30 211.02 Depreciation 23.05 11.44 101.49 72.64 36.67 98.09 72.64 36.67 98.09 PBT 0.05 -17.04 -100.29 62.03 6.63 835.60 62.03 6.63 835.60 TAX -13.83 23.45 -158.98 -13.83 28.67 -148.24 -13.83 28.67 -148.24 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 13.88 -40.49 -134.28 75.86 -22.04 -444.19 75.86 -22.04 -444.19 Equity 487.47 487.47 0.00 487.47 487.47 0.00 487.47 487.47 0.00 PBIDTM(%) 7.26 2.55 185.04 9.95 5.49 81.41 9.95 5.49 81.41

The topline surged 80.17% to Rs. 481.43 millions for the December 2018 quarter as against Rs. 267.21 millions during the corresponding quarter last year.A slender decline of -26.80% was recorded to Rs. 8.66  millions from Rs. 11.83 millions in the corresponding previous quarter.Operating profit for the quarter ended December 2018 rose to 44.82 millions as compared to 27.20 millions of corresponding quarter ended December 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 481.43 267.21 80.17 1106.69 804.41 37.58 1072.36 945.33 13.44 Other Income 30.21 44.87 -32.67 119.46 191.75 -37.70 242.69 190.67 27.28 PBIDT 44.82 27.20 64.78 125.51 52.00 141.37 58.83 -114.91 -151.20 Interest 13.19 0.64 1960.94 13.94 3.11 348.23 3.92 4.23 -7.33 PBDT 31.63 26.55 19.13 111.57 48.88 128.25 43.30 -119.14 -136.34 Depreciation 22.97 9.51 141.54 49.59 25.23 96.55 36.67 32.52 12.76 PBT 8.66 17.04 -49.18 61.98 23.67 161.85 6.63 -151.66 -104.37 TAX 0.00 5.22 0.00 0.00 5.22 -100.00 28.67 0.00 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 8.66 11.83 -26.80 61.98 18.46 235.75 -22.04 -151.66 -85.47 Equity 487.47 487.47 0.00 487.47 487.47 0.00 487.47 487.47 0.00 PBIDTM(%) 9.31 10.18 -8.51 11.34 6.46 75.44 5.49 -12.16 -145.13

The Sales for the quarter ended September 2018 of Rs. 362.41 millions rose by 37.08% from Rs. 264.38 millions.The Net Profit of the company registered a slight decline of -20.16% to Rs. 27.13  millions from Rs. 33.98 millions.Operating profit for the quarter ended September 2018 rose to 45.60 millions as compared to 42.85 millions of corresponding quarter ended September 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201809 201709 % Var 201809 201709 % Var 201803 201703 % Var Sales 362.41 264.38 37.08 625.26 537.20 16.39 1072.36 945.33 13.44 Other Income 45.69 102.49 -55.42 89.25 146.88 -39.24 242.69 190.67 27.28 PBIDT 45.60 42.85 6.42 80.69 24.80 225.36 58.83 -114.91 -151.20 Interest 0.62 0.72 -13.89 0.75 2.47 -69.64 3.92 4.23 -7.33 PBDT 44.98 42.13 6.76 79.94 22.33 257.99 43.30 -119.14 -136.34 Depreciation 17.85 8.17 118.48 26.62 15.72 69.34 36.67 32.52 12.76 PBT 27.13 33.98 -20.16 53.32 6.63 704.22 6.63 -151.66 -104.37 TAX 0.00 0.00 0.00 0.00 0.00 0.00 28.67 0.00 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 27.13 33.98 -20.16 53.32 6.63 704.22 -22.04 -151.66 -85.47 Equity 487.47 487.47 0.00 487.47 487.47 0.00 487.47 487.47 0.00 PBIDTM(%) 12.58 16.22 -22.40 12.91 4.62 179.54 5.49 -12.16 -145.13

The revenue slipped marginally during the June 2018 quarter. A decline of about Rs. 262.85 millions was observed as compared to Rs. 272.82 millions during the corresponding quarter last year.The Total Profit for the quarter ended June 2018 of Rs. 26.19 millions grew from Rs.-27.35 millions Operating profit Margin for the quarter ended June 2018 improved to 35.09% as compared to -18.05% of corresponding quarter ended June 2017 (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 262.85 272.82 -3.65 262.85 272.82 -3.65 1072.36 945.33 13.44 Other Income 43.56 44.39 -1.87 43.56 44.39 -1.87 242.69 190.67 27.28 PBIDT 35.09 -18.05 -294.40 35.09 -18.05 -294.40 58.83 -114.91 -151.20 Interest 0.13 1.75 -92.57 0.13 1.75 -92.57 3.92 4.23 -7.33 PBDT 34.96 -19.80 -276.57 34.96 -19.80 -276.57 43.30 -119.14 -136.34 Depreciation 8.77 7.55 16.16 8.77 7.55 16.16 36.67 32.52 12.76 PBT 26.19 -27.35 -195.76 26.19 -27.35 -195.76 6.63 -151.66 -104.37 TAX 0.00 0.00 0.00 0.00 0.00 0.00 28.67 0.00 0.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 26.19 -27.35 -195.76 26.19 -27.35 -195.76 -22.04 -151.66 -85.47 Equity 487.47 487.47 0.00 487.47 487.47 0.00 487.47 487.47 0.00 PBIDTM(%) 13.35 -6.62 -301.78 13.35 -6.62 -301.78 5.49 -12.16 -145.13

Sequent Scientific is currently trading at Rs. 57.75, up by 6.15 points or 11.92% from its previous closing of Rs. 51.60 on the BSE.The scrip opened at Rs. 52.40 and has touched a high and low of Rs. 61.70 and Rs. 52.40 respectively. So far 143455 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 127.51 on 21-Sep-2017 and a 52 week low of Rs. 44.65 on 05-Jun-2018.Last one week high and low of the scrip stood at Rs. 61.70 and Rs. 50.10 respectively. The current market cap of the company is Rs. 1395.39 crore.The promoters holding in the company stood at 57.28%, while Institutions and Non-Institutions held 17.23% and 25.49% respectively.Sequent Scientific’s subsidiary -- Alivira Animal Health -- has received EU GMP approval from Bulgarian authority`s for its manufacturing unit in Ankara, Turkey. With this approval, Alivira now has 4 EU GMP certified manufacturing units, with one each in Turkey, Spain, Germany and India.Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world`s largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.

SeQuent Scientific is currently trading at Rs. 70.90, up by 2.65 points or 3.88% from its previous closing of Rs. 68.25 on the BSE.The scrip opened at Rs. 70.40 and has touched a high and low of Rs. 71.00 and Rs. 69.55 respectively. So far 18,000 shares were traded on the counter.The BSE group `T` stock of face value Rs. 2 has touched a 52 week high of Rs. 140.09 on 02-May-2017 and a 52 week low of Rs. 61.95 on 06-Feb-2018.Last one week high and low of the scrip stood at Rs. 71.80 and Rs. 66.50 respectively. The current market cap of the company is Rs. 1,728.00 crore.The promoters holding in the company stood at 57.28%, while Institutions and Non-Institutions held 17.09% and 25.63% respectively.SeQuent Scientific’s wholly owned subsidiary - Alivira Animal Health (Alivira) through Alivira Ireland, has signed an agreement with simultaneous closing to acquire 100% of Bremer Pharma, Zydus Cadila’s Animal Health Business in Germany.This acquisition provides Alivira’s with a beta-lactam & non-beta lactam injectables facility for EU markets, which compliments its Orals & Powders beta-lactam and non-beta lactam facility based at Barcelona in Spain. EU is Alivira’s largest market accounting to 60% of revenues.With this acquisition, Alivira is a $150 million business on annualized basis with presence in 95+ countries. Alivira has strong presence in the formulations business in key veterinary markets of Europe, LATAM, India, Turkey, Africa and South East Asian countries.Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world`s largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.

The sales is pegged at Rs. 267.21 millions for the December 2017 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 302.48 millions during the year-ago period.The Total Profit for the quarter ended December 2017 of Rs. 11.83 millions grew from Rs.-71.47 millions Operating profit Margin for the quarter ended December 2017 improved to 27.20% as compared to -54.11% of corresponding quarter ended December 2016 (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 267.21 302.48 -11.66 2480.26 2150.23 15.35 3922.13 4086.71 -4.03 Other Income 44.87 35.87 25.09 195.48 125.66 55.56 200.94 155.53 29.20 PBIDT 27.20 -54.11 -150.27 371.19 77.45 379.26 335.15 510.78 -34.38 Interest 0.64 3.55 -81.97 43.69 42.80 2.08 83.60 164.42 -49.15 PBDT 26.55 -57.67 -146.04 327.49 34.64 845.41 251.54 346.36 -27.38 Depreciation 9.51 13.80 -31.09 133.08 131.73 1.02 251.66 241.80 4.08 PBT 17.04 -71.47 -123.84 194.41 -97.09 -300.24 -0.12 104.56 -100.11 TAX 5.22 0.00 0.00 5.22 0.00 0.00 0.00 0.69 -100.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 11.83 -71.47 -116.55 189.20 -97.09 -294.87 -0.12 103.87 -100.12 Equity 487.47 487.47 0.00 487.47 487.47 0.00 487.47 476.47 2.31 PBIDTM(%) 10.18 -17.89 -156.87 14.97 3.60 315.50 8.54 12.50 -31.63

A fair growth of 23.80% in the revenue at Rs. 1116.85 millions was reported in the June 2017 quarter as compared to Rs. 902.13 millions during year-ago period.The Total Profit for the quarter ended June 2017 of Rs. 55.32 millions grew from Rs.-19.17 millionsOperating Profit saw a handsome growth to 132.05 millions from 59.26 millions in the quarter ended June 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201706 201606 % Var 201706 201606 % Var 201703 201603 % Var Sales 1116.85 902.13 23.80 1116.85 902.13 23.80 3922.13 4086.71 -4.03 Other Income 46.52 39.67 17.27 46.52 39.67 17.27 200.94 155.53 29.20 PBIDT 132.05 59.26 122.83 132.05 59.26 122.83 335.15 510.78 -34.38 Interest 20.22 21.60 -6.39 20.22 21.60 -6.39 83.60 164.42 -49.15 PBDT 111.83 37.66 196.95 111.83 37.66 196.95 251.54 346.36 -27.38 Depreciation 56.51 56.83 -0.56 56.51 56.83 -0.56 251.66 241.80 4.08 PBT 55.32 -19.17 -388.58 55.32 -19.17 -388.58 -0.12 104.56 -100.11 TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.69 -100.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 55.32 -19.17 -388.58 55.32 -19.17 -388.58 -0.12 103.87 -100.12 Equity 487.47 476.47 2.31 487.47 476.47 2.31 487.47 476.47 2.31 PBIDTM(%) 11.82 6.57 79.99 11.82 6.57 79.99 8.54 12.50 -31.63

Sequent Scientific is currently trading at Rs. 124.00, up by 0.20 points or 0.16% from its previous closing of Rs. 123.80 on the BSE.The scrip opened at Rs. 124.60 and has touched a high and low of Rs. 126.00 and Rs. 123.20 respectively. So far 5585 shares were traded on the counter.The BSE group `B` stock of face value Rs. 2 has touched a 52 week high of Rs. 150.55 on 03-Feb-2017 and a 52 week low of Rs. 102.00 on 09-Dec-2016.Last one week high and low of the scrip stood at Rs. 129.00 and Rs. 115.90 respectively. The current market cap of the company is Rs. 3027.20 crore.The promoters holding in the company stood at 57.24%, while Institutions and Non-Institutions held 18.69% and 24.07% respectively.Alivira Animal Health (Alivira), a wholly owned subsidiary of SeQuent Scientific (SeQuent) has received three product registrations in Ukraine. The products have already been shipped to Ukraine and will be launched shortly. Ukraine is the largest egg and poultry market in Europe growing at over 8% year on year largely on account of expanding exports to European Union, Middle East, and Asia.Alivira entered Ukraine in October 2016 and has since developed and initiated registration of a strong portfolio of nutrition products which bode well with the market’s transition from traditional antibiotics towards nutrition. Ukraine would make a significant contribution to Alivira’s growth as another six products are under registration. Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world`s largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.